NCT03980509已完成1 期
A "Window Trial" on Curcumin, the Active Compound in Turmeric, for Invasive Breast Cancer Primary Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 22
- 试验地点
- 1
- 主要终点
- Change in tumor proliferation rate
研究概览
简要总结
The purpose of this study is to determine whether oral administration of curcumin causes biological changes in primary tumors of breast cancer patients.
详细描述
The purpose of this study is to determine whether oral administration of Curcuma longa extract causes biological changes related to apoptosis (DNA fragmentation) and cell proliferation (Ki67) in primary tumors of breast cancer patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed invasive breast cancer (stages I, II, or III) with primary tumor(s) ≥ 1.0 cm on mammogram, ultrasound, MRI, or physical exam
- •18 years of age or older
- •Subject must understand risks and benefits of the protocol and be able to give informed consent
- •Women of childbearing potential (WOCBP) must agree to use an approved form of birth control and to have a negative pregnancy test result within 14 days of registration. WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 consecutive months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes
- •Approved forms of birth control:
- •combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intra-vaginal, or transdermal)
- •progestogen only hormonal contraception associated with inhibition of ovulation (oral, injectable, or implantable)
- •intrauterine device, intrauterine hormone-releasing system
- •bilateral tubal occlusion/ligation
- •vasectomized partner
- •barrier contraception
- •sexual abstinence
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •Adequate hematologic and end organ function
- •Ability and capacity to comply with the study and follow-up procedures
- •Subjects must be scheduled for surgery at MUSC no less than 5 days from the planned start of day 1 and no more than 56 days from the planned start of day 1
- •At least 6 sections of unstained slides should be obtained. If sufficient slides or tissue is unavailable, the patient will be excluded from the trial
排除标准
- •Subjects undergoing neoadjuvant chemotherapy or neoadjuvant endocrine therapy
- •Subjects with end-stage kidney disease and/or grade II liver dysfunction
- •Subjects who are pregnant or are lactating.
- •Subjects with bile duct obstruction, gallstones, predisposition to kidney stones(39), or gastrointestinal disorders such as stomach ulcers and hyperacidity disorders(40)
- •Subjects taking anti-coagulants or platelet inhibitors
- •Subjects taking drugs metabolized by CYP3A4, CYP1A2, and CYP2A6 enzymes
- •Subjects taking drugs that interact with P-glycoprotein (P-gp)
- •Subjects taking any of the medications listed under Other Herb-Drug interactions according to the Memorial Sloan Kettering Cancer Center in section 5.
研究组 & 干预措施
Curcumin
Experimental
Curcumin will be given at 500mg by mouth twice a day, immediately after each meal. Curcumin will be given from the time surgical resection is scheduled until the night before surgical resection.
干预措施: Curcumin (Drug)
结局指标
主要结局
Change in tumor proliferation rate
时间窗: Up to 56 days
Change in tumor proliferation rate will be based on apoptosis (DNA fragmentation) and cell proliferation (Ki67) assays in biopsies pre and post treatment with curcumin
次要结局
- Number of adverse events reported(up to 84 days)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Oral Curcumin for the Treatment of Pain of Thumb Base Joint (CMC) ArthritisArthritis of Carpometacarpal Joint of Left ThumbArthritis of Carpometacarpal Joint of Right ThumbNCT06359665Brent DeGeorge100
撤回
2 期
Evaluating Effects of Curcumin in Moderate to Severe AsthmaticsAsthmaNCT04353310Loma Linda University
终止
早期 1 期
Curcumin in Combination With 5FU for Colon CancerMetastatic Colon CancerNCT02724202Baylor Research Institute15
Unknown
不适用
Oral Curcumin Supplementation in Middle-Aged and Older Adults Improves Vascular FunctionVascular AgingNCT01968564University of Colorado, Boulder118
已完成
早期 1 期
Testing the Bioavailability of Phytonutrients, Curcumin and Ursolic AcidBioavailability of PhytonutrientsNCT04421716The University of Texas Health Science Center at San Antonio18